Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

NCT01313390 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Lack of recruitment

Conditions

Head and Neck Cancer

Interventions

DRUG: docetaxel
DRUG: everolimus
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

University College, London